We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-HER2/Neu passive-aggressive immunotherapy.
- Authors
Mortenson, Eric D; Fu, Yang-Xin
- Abstract
Preclinical studies have established that CD8 + T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu therapy also requires CD4 + T cells and CD40/CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
- Publication
Oncoimmunology, 2014, Vol 3, Issue 1, pe27296
- ISSN
2162-4011
- Publication type
Journal Article
- DOI
10.4161/onci.27296